Clinical Trials Sponsored by IASO Pharma Inc.

Total 2369 results

Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Peanut Allergy

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants

Healthy Subjects

United States
Astellas Pharma Global Development, Inc.

Completed

Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review

Acute Myeloid Leukemia (AML)

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors

Tumors | Incurable Platinum Refractory Germ Cell Tumors

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Canada, United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

Schizophrenia

United States
Astellas Pharma Global Development, Inc.

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)

Overactive Bladder (OAB)

United States, Canada
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215

Healthy | Hepatic Impairment

United States
Astellas Pharma Global Development, Inc.

Completed

Registry of Patients Treated With Systemic Mold-Active Triazoles

Invasive Fungal Infection

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) (PLUS)

Overactive Bladder | Benign Prostatic Hyperplasia

United States, Canada, Czechia, France, Germany, Italy, Poland, Spain, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer (FAST)

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction | CLDN18.2-positive Adenocarcinoma of Esophagus | CLDN18.2-positive Gastric Adenocarcinoma

Bulgaria, Czechia, Germany, Latvia, Russian Federation, Ukraine
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia

Fibromyalgia

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

Schizophrenia

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Poland, Czechia, Bulgaria, Hungary, Mexico
Astellas Pharma Global Development, Inc.

Terminated

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

Non-hematologic Malignancies | Pharmacokinetics of ASP9853

United States
Astellas Pharma Global Development, Inc.

Completed

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Germany, Italy
Astellas Pharma Global Development, Inc.

Terminated

Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

Painful Diabetic Peripheral Neuropathy (PDPN)

United States
Astellas Pharma Global Development, Inc.

Completed

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Advanced Solid Tumors

Germany, Czechia, United States, Brazil, Poland, Singapore, Thailand
Astellas Pharma Global Development, Inc.

Withdrawn

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Subjects With NSCLC With an EGFR Activating Mutation
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections

Healthy Subjects | Pharmacokinetics of ASP2408

United States
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses

Healthy Subjects | Pharmacokinetics of ASP4058 | Food Effect of ASP4058

United States
gicare Pharma Inc.
Algorithme Pharma Inc; JSS Medical Research Inc.

Completed

A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy

Pain | Cancer | Colonic Diseases

United States, Canada
Astellas Pharma Global Development, Inc.
Medivation, Inc.

Approved for marketing

Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Metastatic Castration-Resistant Prostate Cancer
InnoCare Pharma Inc.

Not yet recruiting

A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL

Mantle Cell Lymphoma
ImmunoRx Pharma Inc.

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants

Healthy Participants

Netherlands
Telios Pharma, Inc.

Recruiting

A Study Of TL-925 For The Treatment of AC

Allergic Conjunctivitis

United States
Astellas Pharma Inc

Recruiting

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause (Starlight 2)

Hot Flashes

Japan
Telios Pharma, Inc.

Recruiting

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Lantern Pharma Inc.

Recruiting

A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors

Advanced Solid Tumor | Relapsed or Refractory Lymphomas

United States
Acasti Pharma Inc.

Recruiting

Safety and Tolerability of GTX-104 Compared With Oral Nimodipine in Patients With aSAH (STRIVE-ON)

Aneurysmal Subarachnoid Hemorrhage (aSAH)

United States
Cho Pharma Inc.

Recruiting

A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Non-Hodgkin Lymphoma

Taiwan, United States
aTyr Pharma, Inc.

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Interstitial Lung Disease

United States
Kringle Pharma, Inc.

Recruiting

Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar

Vocal Fold Scar

Japan
Lantern Pharma Inc.

Recruiting

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (HARMONIC)

Carcinoma, Non-Small-Cell Lung | Adenocarcinoma of Lung

United States
Astellas Pharma Inc

Recruiting

A Study of ASP3082 in Adults With Previously Treated Solid Tumors

Solid Tumor

United States, Japan
CanWell Pharma Inc.

Recruiting

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

Solid Tumor | Cancer Metastatic

United States
Averitas Pharma, Inc.

Recruiting

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

Post Surgical Neuropathic Pain

United States, Spain, France, Netherlands, Poland, United Kingdom
Astellas Pharma Inc

Recruiting

Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

Rheumatoid Arthritis (RA)

Japan
Sinew Pharma Inc.

Not yet recruiting

A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis
Esperas Pharma Inc.

Recruiting

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Neoplasms | Soft Tissue Sarcoma | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Rectal Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Colon Cancer | Solid Tumors | Pancreas Cancer

Canada, United States, Croatia, Poland
Astellas Pharma Inc

Active, not recruiting

Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia

Renal Anemia

Japan
Astellas Pharma Inc

Active, not recruiting

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

China, Malaysia, Russian Federation, Singapore, Thailand
Medexus Pharma, Inc.

Completed

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Hemophilia B

Turkey, Brazil, Georgia, Moldova, Republic of, South Africa, Ukraine
Astellas Pharma Inc

Terminated

A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery

Melanoma | Breast Cancer | Sentinel Lymph Node Biopsy

United States
Zurex Pharma, Inc.

Completed

Perioperative Patient Skin Antiseptic Preparation Evaluation

Surgical Site Infection

United States
MEI Pharma, Inc.

Terminated

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)

United States, Spain, Korea, Republic of, Belgium, Taiwan, Germany, France, Italy, Australia, Poland, New Zealand, United Kingdom, Austria, Switzerland
OBI Pharma, Inc

Terminated

Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

Locally Advanced Solid Tumor

United States
Vincerx Pharma, Inc.

Terminated

A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Relapsed Non Hodgkin Lymphoma | Richter Syndrome | MYC Amplification | MYC Overexpression | MYC Translocation

United States, Poland
Astellas Pharma Inc

Completed

A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery

Laparoscopic/Minimally Invasive Colorectal Surgery

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

Mydriasis | Dilation

United States

3

Subscribe